Sp-722

Sp‑722 is an experimental small molecule inhibitor originally identified as a ligand for site-directed drug discovery using the "tethering" approach. It is a synthetic derivative of glutamic acid and D-proline, classified chemically as a sulfonamide and N-acylpyrrolidine. Sp‑722 was developed as an inhibitor of thymidylate synthase, an essential enzyme in pyrimidine metabolism with therapeutic applications in cancer and infectious diseases. The compound was used to nucleate structure-based drug design efforts targeting thymidylate synthase, but has not advanced beyond early-stage research[1][3][8].

Other names

4-[[glutamic acid]-carbonyl]-benzene-sulfonyl-d-prolineCHEMBL325414CHEMBL-325414CHEMBL 325414CHEBI:46068N-[4-(D-prolinosulfonyl)benzoyl]-L-glutamic acidN-[(4-{[(2R)-2-carboxypyrrolidin-1-yl]sulfonyl}phenyl)carbonyl]-L-glutamic acid(2S)-2-{4-[ (2R)-2-carboxypyrrolidin -1 - ylsulfonyl ] phenyl }formamido pentanedioic acid(2S)-2-[ [ 4-[ (2R ) - 2-carboxypyrrolidin -1 - yl ] sulfonyl benzoyl ] amino ] pentanedioic acid